2013
DOI: 10.3389/conf.fimmu.2013.02.00925
|View full text |Cite
|
Sign up to set email alerts
|

Optimising regulatory T cell (Treg) depletion in combination with chemotherapy for enhanced anti-tumour immunity

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2014
2014
2014
2014

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…Additionally, the same study observed a reduced Treg cell population in peripheral blood from NSCLC patients after four cycles of docetaxel-based chemotherapy. In another small study, effect of a low dose of cyclophosphamide (CTX) was investigated for selective depletion of Treg cells in conjunction with pemetrexed-based NSCLC chemotherapy [90]. While Treg cell numbers were unaffected, activated T-effector cells were increased, suggesting CTX may affect Treg cell function.…”
Section: Th1 and Th2 Cells In Immune Modulationmentioning
confidence: 99%
“…Additionally, the same study observed a reduced Treg cell population in peripheral blood from NSCLC patients after four cycles of docetaxel-based chemotherapy. In another small study, effect of a low dose of cyclophosphamide (CTX) was investigated for selective depletion of Treg cells in conjunction with pemetrexed-based NSCLC chemotherapy [90]. While Treg cell numbers were unaffected, activated T-effector cells were increased, suggesting CTX may affect Treg cell function.…”
Section: Th1 and Th2 Cells In Immune Modulationmentioning
confidence: 99%